Top Companies in Single Cell Sequencing

The single cell sequencing market is projected to reach USD 3.46 billion by 2030 from USD 1.95 billion in 2025, at a CAGR of 12.2% during the forecast period. A key factor driving the market growth is the broad uptake of single cell sequencing for clinical & translational applications. This growing demand encourages continuous improvements in sequencing technologies, making them more accurate, easier to use, and suitable for research and clinical applications. As these technologies improve, there is also a rising need for high-resolution data, fueling interest in combining multiple data types, such as gene expression, protein levels, and spatial location through integrated multi-omics and spatial transcriptomics approaches. These methods are instrumental in fields like cancer and neuroscience, where understanding the exact position and behavior of cells within tissues is essential.

To know about the assumptions considered for the study download the pdf brochure

The global single-cell sequencing market is consolidated and is dominated by a few companies, such as 10x Genomics (US), BD (US), Illumina (US), among others. These companies are launching new products, expanding services, and forming strategic collaborations, aligning with the growing research and clinical application demands. Furthermore, collaborations between leading technology providers and research institutions are crucial in scaling high-throughput single-cell efforts. For instance, in February 2025, Illumina partnered with Broad Clinical Labs to support the creation of a 5-billion-cell atlas. By integrating Illumina’s sequencing platforms and data analysis tools with Broad’s expertise in functional genomics and Perturb-seq, this partnership demonstrates how end-to-end solutions are critical for large-scale, discovery-driven research.

10x Genomics (US)

10x Genomics is a leading company in the single cell sequencing market, known for its strong product portfolio, broad adoption, and collaborations with key industry players. Its Chromium platform is the most widely used system for the pre-sequencing stage, especially in single-cell library preparation. This strong position is supported by collaborations with major sequencing companies, making their technologies compatible with 10x Genomics’ chemistry. For instance, in February 2025, Oxford Nanopore Technologies expanded its partnership with 10x Genomics to support compatibility between 10x’s GEM-X single-cell kits and Oxford’s V14 sequencing chemistry. This move highlights how leading sequencing companies align with 10x to access its large user base in the research community. The company is also involved in large-scale scientific collaborations, reinforcing its role as a key enabler of high-throughput single-cell analysis. For example, in February 2025, the Chan Zuckerberg Initiative launched the Billion Cells Project with 10x Genomics and Ultima Genomics. The project will use 10x’s Chromium GEM-X platform to analyze over one billion cells, helping to build advanced AI models for studying gene function and disease.

Illumina, Inc. (US)

Illumina is a leading company in the single-cell sequencing market, especially in the sequencing phase of the workflow. Researchers widely utilize its platforms for their accuracy, scalability, and compatibility with upstream single-cell technologies. Illumina supports its position by improving product integration and performance. For instance, in August 2023, Illumina announced that sequencing data from 10x Genomics’ Chromium Single Cell Multiome ATAC + Gene Expression assay is available on the NovaSeq X Series through BaseSpace Sequence Hub. This allows researchers to study chromatin accessibility and gene expression in the same single cell by combining 10x Genomics' assay with Illumina’s sequencing speed and accuracy. Illumina is also making single-cell sequencing more accessible. In January 2025, the company launched Illumina Single Cell 3’ RNA Prep, a simple, end-to-end kit for analyzing gene expression in hundreds to millions of cells. The company is also partnering with major institutions, such as collaborating with Broad Clinical Labs, in February 2025 to create a 5 billion single-cell atlas over three years. This partnership combines Illumina’s sequencing systems, prep kits, flow cells, and DRAGEN analysis software with Broad’s high-throughput CRISPR Perturb-seq workflows, offering a functional genomics and drug discovery solution.

BD (US)

BD (Becton, Dickinson and Company) is a leading player in the single cell sequencing market, particularly in the pre-sequencing stages, where it offers a complete solution spanning instruments, reagents, and software. Researchers widely use the company’s systems for their reliability, ease of use, and compatibility with complex biological workflows. In October 2024, BD launched its BD OMICS-One XT WTA Assay, a high-throughput reagent kit designed with the Hamilton Microlab NGS STAR liquid-handling platform. This kit helps genomics labs automate and standardize their single-cell workflows, reducing manual steps and improving efficiency. Additionally, in February 2025, the IDIBAPS research institute (Clínic Barcelona) incorporated the BD Rhapsody HT Single-Cell Analysis System into its Functional Genomics Platform. This high-throughput system, featuring microwell-based cell isolation and eight-lane cartridges, can analyze up to 800,000 cells per run, supporting whole transcriptome analysis, targeted mRNA profiling, Ab-Seq, TCR/BCR sequencing, and ATAC-Seq. BD introduced the BD Rhapsody Scanner, a real-time visual QC tool that integrates with high-throughput and low-throughput systems to support quality and scalability further. This tool enhances decision-making during experiments and is especially useful when working with rare or complex cell types.

Market Ranking

The single-cell sequencing products market is consolidated, with five major players collectively holding a 70-75% market share. At the same time, the single-cell sequencing services market is fragmented, with leading players holding 10-15% market share.

10x Genomics is a market leader in pre-sequencing, especially for single-cell RNA, ATAC, and multiome applications. Its Chromium platform is widely used for cell isolation and barcoding, helping researchers process thousands of cells efficiently. BD focuses on sample preparation and cell isolation. Its instruments and reagents are commonly used in research involving immune cells and complex tissues, supporting reliable and high-quality single-cell data generation. Illumina is the leading provider in the sequencing phase. Over 85% of researchers surveyed use Illumina platforms for single-cell sequencing. Its NovaSeq systems offer high throughput, accuracy, and compatibility with popular single-cell kits. Illumina also continues to invest in prep kits and software to improve usability. Thermo Fisher Scientific, Inc. provides library prep kits, reagents, and analysis tools. Its broad portfolio supports various single-cell workflows across research and clinical labs. Danaher, through brands like Beckman Coulter and Leica Microsystems, offers tools for cell sorting, sample preparation, and spatial analysis. These solutions are important for researchers studying cell location and behavior before sequencing. Smaller or regional players share the remaining 25–30% of the product market, many offering niche or specialized tools.

Related Reports:

Single Cell Sequencing Market by Product (Reagents & Kits, Platforms, Software), Workflow (Presequencing), Service (Sample Preparation, Bioinformatics), Sequencing (scRNA, scDNA), Application (Research, Diagnostic), End User - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets Inc.
1615 South Congress Ave.
Suite 103,
Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com